The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of Prograf and Advagraf.

Trial Profile

The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of Prograf and Advagraf.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 09 May 2014 Accrual to date is 29% according to United Kingdom Clinical Research Network.
    • 03 May 2014 Status changed from recruiting to active, no longer recruiting.
    • 27 Mar 2014 According to UK Clinical Trials Register, status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top